| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Belimumab |
| Brand | Benlysta® |
| Indication | As add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy. |
| Assessment Process | |
| Rapid review commissioned | 11/08/2011 |
| Rapid review completed | 31/08/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
Not considered cost-effective due to non-submission of full pharmacoeconomic evaluation.